Durmugier J, Sabia S. Epidemiology of Alzheimer’s disease: latest trends. Rev Prat. 2020;70:149–51.
World Health Organization. Dementia. 2022 [cited 2022 Oct 19]. Available from: https://www.who.int/news-room/fact-sheets/detail/dementia
Beam CR, Kaneshiro C, Jang JY, Reynolds CA, Pedersen NL, Gatz M. Differences between women and men in incidence rates of dementia and Alzheimer’s disease. J Alzheimer’s Dis. 2018;64:1077–83. Available from: https://www.medra.org/servlet/aliasResolver?alias=iospress&doi=10.3233/JAD-180141.
Viña J, Lloret A. Why women have more Alzheimer’s disease than men: gender and mitochondrial toxicity of amyloid-β peptide. Zhu X, Beal MF, Wang X, Perry G, Smith MA, editors. J Alzheimer’s Dis. 2010;20:S527-33. Available from: https://www.medra.org/servlet/aliasResolver?alias=iospress&doi=10.3233/JAD-2010-100501.
Mielke MM, Ferretti MT, Iulita MF, Hayden K, Khachaturian AS. Sex and gender in Alzheimer’s disease – Does it matter? Alzheimer’s Dement. 2018;14:1101–3. Available from: https://alz-journals.onlinelibrary.wiley.com/doi/10.1016/j.jalz.2018.08.003.
Alzheimer’s disease facts and figures. Alzheimer’s Dement. 2021;17:327–406.
Mosconi L, Berti V, Quinn C, McHugh P, Petrongolo G, Varsavsky I, et al. Sex differences in Alzheimer risk. Neurology. 2017;89:1382–90. Available from: https://www.neurology.org/doi/10.1212/WNL.0000000000004425.
Rocca WA, Mielke MM, Vemuri P, Miller VM. Sex and gender differences in the causes of dementia: A narrative review. Maturitas. 2014;79:196–201. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0378512214001601.
Mauvais-Jarvis F, Arnold AP, Reue K. A guide for the design of pre-clinical studies on sex differences in metabolism. Cell Metab. 2017;25:1216–30. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1550413117302863.
Castro-Aldrete L, Moser MV, Putignano G, Ferretti MT, Schumacher Dimech A, Santuccione Chadha A. Sex and gender considerations in Alzheimer’s disease: The Women’s Brain Project contribution. Front Aging Neurosci. 2023;15. Available from: https://www.frontiersin.org/articles/10.3389/fnagi.2023.1105620/full
Karp NA, Reavey N. Sex bias in preclinical research and an exploration of how to change the status quo. Br J Pharmacol. 2019;176:4107–18. Available from: https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.14539.
Rhea EM, Banks WA. Interactions of Lipids, Lipoproteins, and Apolipoproteins with the Blood-Brain Barrier. Pharm Res. 2021;38:1469–75. Available from: https://link.springer.com/10.1007/s11095-021-03098-6.
Desai BS, Monahan AJ, Carvey PM, Hendey B. Blood-brain barrier pathology in Alzheimer’s and Parkinson’s disease: implications for drug therapy. Cell Transplant. 2007;16:285–99. Available from: http://journals.sagepub.com/doi/10.3727/000000007783464731.
Takechi R, Galloway S, Pallebage-Gamarallage MMS, Lam V, Mamo JCL. Dietary fats, cerebrovasculature integrity and Alzheimer’s disease risk. Prog Lipid Res. 2010;49:159–70. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0163782709000563.
Hane FT, Robinson M, Lee BY, Bai O, Leonenko Z, Albert MS. Recent progress in Alzheimer’s disease research, part 3: diagnosis and treatment. J Alzheimer’s Dis. 2017;57:645–65. Available from: https://www.medra.org/servlet/aliasResolver?alias=iospress&doi=10.3233/JAD-160907.
Guzman-Martinez L, Maccioni RB, Farías GA, Fuentes P, Navarrete LP. Biomarkers for Alzheimer’s Disease. Curr Alzheimer Res. 2019;16:518–28. Available from: https://www.eurekaselect.com/172184/article.
Kao Y-C, Ho P-C, Tu Y-K, Jou I-M, Tsai K-J. Lipids and Alzheimer’s Disease. Int J Mol Sci. 2020;21:1505. Available from: https://www.mdpi.com/1422-0067/21/4/1505.
Zhang L, Li L, Meng F, Yu J, He F, Lin Y, et al. Serum metabolites differentiate amnestic mild cognitive impairment from healthy controls and predict early Alzheimer’s disease via untargeted lipidomics analysis. Front Neurol. 2021;12. Available from: https://www.frontiersin.org/articles/10.3389/fneur.2021.704582/full
Agarwal M, Khan S. Plasma lipids as biomarkers for Alzheimer’s disease: a systematic review. Cureus. 2020; Available from: https://www.cureus.com/articles/44978-plasma-lipids-as-biomarkers-for-alzheimers-disease-a-systematic-review
Chew H, Solomon VA, Fonteh AN. Involvement of Lipids in Alzheimer’s Disease Pathology and Potential Therapies. Front Physiol. 2020;11. https://www.frontiersin.org/article/10.3389/fphys.2020.00598/full
Reitz C, Mayeux R. Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol. 2014;88:640–51. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0006295213008083.
Liu Y, Thalamuthu A, Mather KA, Crawford J, Ulanova M, Wong MWK, et al. Plasma lipidome is dysregulated in Alzheimer’s disease and is associated with disease risk genes. Transl Psychiatry. 2021;11:344. Available from: https://www.nature.com/articles/s41398-021-01362-2.
Proitsi P, Kim M, Whiley L, Simmons A, Sattlecker M, Velayudhan L, et al. Association of blood lipids with Alzheimer’s disease: A comprehensive lipidomics analysis. Alzheimer’s Dement. 2017;13:140–51. Available from: https://alz-journals.onlinelibrary.wiley.com/doi/10.1016/j.jalz.2016.08.003.
Ferré-González L, Lloret A, Cháfer-Pericás C. Systematic review of brain and blood lipidomics in Alzheimer’s disease mouse models. Prog Lipid Res. 2023;90:101223. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0163782723000139.
Mielke MM, Haughey NJ, Han D, An Y, Bandaru VVR, Lyketsos CG, et al. The association between plasma ceramides and sphingomyelins and risk of Alzheimer’s disease differs by sex and APOE in the Baltimore longitudinal study of aging. Mielke M, Martinez P, editors. J Alzheimer’s Dis. 2017;60:819–28. Available from: https://www.medra.org/servlet/aliasResolver?alias=iospress&doi=10.3233/JAD-160925.
Wong MW, Braidy N, Poljak A, Pickford R, Thambisetty M, Sachdev PS. Dysregulation of lipids in Alzheimer’s disease and their role as potential biomarkers. Alzheimer’s Dement. 2017;13:810–27. Available from: https://alz-journals.onlinelibrary.wiley.com/doi/10.1016/j.jalz.2017.01.008.
Cutler RG, Kelly J, Storie K, Pedersen WA, Tammara A, Hatanpaa K, et al. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer’s disease. Proc Natl Acad Sci. 2004;101:2070–5. Available from: https://pnas.org/doi/full/10.1073/pnas.0305799101.
Li W, Zhou Y, Luo Z, Tang R, Sun Y, He Q, et al. Lipidomic markers for the prediction of progression from mild cognitive impairment to Alzheimer’s disease. FASEB J. 2023;37. Available from: https://faseb.onlinelibrary.wiley.com/doi/10.1096/fj.202201584RR
Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, et al. Mutant presenilins specifically elevate the levels of the 42 residue β-amyloid peptide in vivo: evidence for augmentation of a 42-specific γ secretase. Hum Mol Genet. 2004;13:159–70. Available from: https://academic.oup.com/hmg/article-lookup/doi/10.1093/hmg/ddh019.
Volianskis A, Køstner R, Mølgaard M, Hass S, Jensen MS. Episodic memory deficits are not related to altered glutamatergic synaptic transmission and plasticity in the CA1 hippocampus of the APPswe/PS1ΔE9-deleted transgenic mice model of β-amyloidosis. Neurobiol Aging. 2010;31:1173–87. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0197458008002844.
McLean AC, Valenzuela N, Fai S, Bennett SAL. Performing vaginal lavage, crystal violet staining, and vaginal cytological evaluation for mouse estrous cycle staging identification. J Vis Exp. 2012; Available from: https://app.jove.com/t/4389
Ferré-González L, Balaguer Á, Roca M, Ftara A, Lloret A, Cháfer-Pericás C. Brain areas lipidomics in female transgenic mouse model of Alzheimer’s disease. Sci Rep. 2024;14:870. Available from: https://www.nature.com/articles/s41598-024-51463-3.
Alcoriza-Balaguer MI, García-Cañaveras JC, Ripoll-Esteve FJ, Roca M, Lahoz A. LipidMS 3.0: an R-package and a web-based tool for LC-MS/MS data processing and lipid annotation. Borgwardt K, editor. Bioinformatics. 2022;38:4826–8. Available from: https://academic.oup.com/bioinformatics/article/38/20/4826/6675453.
Mowbray FI, Fox-Wasylyshyn SM, El-Masri MM. Univariate outliers: a conceptual overview for the nurse researcher. Can J Nurs Res. 2019;51:31–7. Available from: http://journals.sagepub.com/doi/10.1177/0844562118786647.
Ajayi AF, Akhigbe RE. Staging of the estrous cycle and induction of estrus in experimental rodents: an update. Fertil Res Pract. 2020;6:5. Available from: https://fertilityresearchandpractice.biomedcentral.com/articles/10.1186/s40738-020-00074-3.
Tajima Y, Ishikawa M, Maekawa K, Murayama M, Senoo Y, Nishimaki-Mogami T, et al. Lipidomic analysis of brain tissues and plasma in a mouse model expressing mutated human amyloid precursor protein/tau for Alzheimer’s disease. Lipids Health Dis. 2013;12:68. Available from: https://lipidworld.biomedcentral.com/articles/10.1186/1476-511X-12-68.
Shang Y, Mishra A, Wang T, Wang Y, Desai M, Chen S, et al. Evidence in support of chromosomal sex influencing plasma based metabolome vs APOE genotype influencing brain metabolome profile in humanized APOE male and female mice. Reddy H, editor. PLoS One. 2020;15:e0225392. Available from: https://doi.org/10.1371/journal.pone.0225392.
Abdullah L, Evans JE, Emmerich T, Crynen G, Shackleton B, Keegan AP, et al. APOE ε4 specific imbalance of arachidonic acid and docosahexaenoic acid in serum phospholipids identifies individuals with preclinical mild cognitive impairment/Alzheimer’s disease. Aging (Albany NY). 2017;9:964–85. Available from: https://www.aging-us.com/lookup/doi/10.18632/aging.101203.
Zhang X, Liu W, Zan J, Wu C, Tan W. Untargeted lipidomics reveals progression of early Alzheimer’s disease in APP/PS1 transgenic mice. Sci Rep. 2020;10:14509. Available from: https://www.nature.com/articles/s41598-020-71510-z.
den Hoedt S, Crivelli SM, Leijten FPJ, Losen M, Stevens JAA, Mané-Damas M, et al. Effects of sex, age, and apolipoprotein E genotype on brain ceramides and sphingosine-1-phosphate in Alzheimer’s disease and control mice. Front Aging Neurosci. 2021;13. Available from: https://www.frontiersin.org/articles/10.3389/fnagi.2021.765252/full
Canhada S, Castro K, Perry IS, Luft VC. Omega-3 fatty acids’ supplementation in Alzheimer’s disease: A systematic review. Nutr Neurosci. 2018;21:529–38. Available from: https://www.tandfonline.com/doi/full/10.1080/1028415X.2017.1321813.
Cunnane SC, Schneider JA, Tangney C, Tremblay-Mercier J, Fortier M, Bennett DA, et al. Plasma and brain fatty acid profiles in mild cognitive impairment and Alzheimer’s disease. J Alzheimer’s Dis. 2012;29:691–7. Available from: https://www.medra.org/servlet/aliasResolver?alias=iospress&doi=10.3233/JAD-2012-110629.
Wang D-C, Sun C-H, Liu L-Y, Sun X-H, Jin X-W, Song W-L, et al. Serum fatty acid profiles using GC-MS and multivariate statistical analysis: potential biomarkers of Alzheimer’s disease. Neurobiol Aging. 2012;33:1057–66. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0197458010003933.
Yin F. Lipid metabolism and Alzheimer’s disease: clinical evidence, mechanistic link and therapeutic promise. FEBS J. 2023;290:1420–53. Available from: https://onlinelibrary.wiley.com/doi/10.1111/febs.16344.
Wu J, Fu B, Lei H, Tang H, Wang Y. Gender differences of peripheral plasma and liver metabolic profiling in APP/PS1 transgenic AD mice. Neuroscience. 2016;332:160–9. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0306452216302883.
Zeng B, Zhao G, Liu HL. The differential effect of treadmill exercise intensity on hippocampal soluble Aβ and lipid metabolism in APP/PS1 mice. Neuroscience. 2020;430:73–81. Available from: https://linkinghub.elsevier.com/retrieve/pii/S030645222030018X.
Farooqui AA, Horrocks LA, Farooqui T. Interactions between neural membrane glycerophospholipid and sphingolipid mediators: A recipe for neural cell survival or suicide. J Neurosci Res. 2007;85:1834–50. Available from: https://onlinelibrary.wiley.com/doi/10.1002/jnr.21268.
Vance JE, Tasseva G. Formation and function of phosphatidylserine and phosphatidylethanolamine in mammalian cells. Biochim Biophys Acta – Mol Cell Biol Lipids. 2013;1831:543–54. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1388198112001874.
Pan X, Green BD. Temporal Effects of Neuron-specific beta-secretase 1 (BACE1) Knock-in on the Mouse Brain Metabolome: Implications for Alzheimer’s Disease. Neuroscience. 2019;397:138–46. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0306452218307644.
González-Domínguez R, García-Barrera T, Vitorica J, Gómez-Ariza JL. Metabolomic screening of regional brain alterations in the APP/PS1 transgenic model of Alzheimer’s disease by direct infusion mass spectrometry. J Pharm Biomed Anal. 2015;102:425–35. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0731708514005007.
Khorani M, Bobe G, Matthews DG, Magana AA, Caruso M, Gray NE, et al. The impact of the hAPP695SW transgene and associated Amyloid-β accumulation on murine hippocampal biochemical pathways. J Alzheimer’s Dis. 2022;85:1601–19. Available from: https://www.medra.org/servlet/aliasResolver?alias=iospress&doi=10.3233/JAD-215084.
González-Domínguez R, García-Barrera T, Vitorica J, Gómez-Ariza JL. Deciphering metabolic abnormalities associated with Alzheimer’s disease in the APP/PS1 mouse model using integrated metabolomic approaches. Biochimie. 2015;110:119–28. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0300908415000103.
Chen Y, Hu D, Zhao L, Tang W, Li B. Unraveling metabolic alterations in transgenic mouse model of Alzheimer’s disease using MALDI MS imaging with 4-aminocinnoline-3-carboxamide matrix. Anal Chim Acta. 2022;1192:339337. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0003267021011636.
Yin F. Lipid metabolism and Alzheimer’s disease: clinical evidence, mechanistic link and therapeutic promise. FEBS J. 2023;290:1420–53. Available from: https://febs.onlinelibrary.wiley.com/doi/10.1111/febs.16344.
Guan Z, Wang Y, Cairns NJ, Lantos PL, Dallner G, Sindelar PJ. Decrease and structural modifications of phosphatidylethanolamine plasmalogen in the brain with Alzheimer disease. J Neuropathol Exp Neurol. 1999;58:740–7. Available from: https://academic.oup.com/jnen/article-lookup/doi/10.1097/00005072-199907000-00008.
Zhao N-N, Sun Y-F, Zong L, Liu S, Song F-R, Liu Z-Q, et al. Serum lipidomics study of Ding-Zhi-Xiao-Wan effect on Alzheimer’s disease using online liquid extraction surface analysis coupled to direct infusion mass spectrometry. Int J Mass Spectrom. 2018;434:29–36. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1387380618301623.
Plucińska K, Dekeryte R, Koss D, Shearer K, Mody N, Whitfield PD, et al. Neuronal human BACE1 knockin induces systemic diabetes in mice. Diabetologia. 2016;59:1513–23. Available from: http://link.springer.com/10.1007/s00125-016-3960-1.
Dorninger F, Moser AB, Kou J, Wiesinger C, Forss-Petter S, Gleiss A, et al. Alterations in the plasma levels of specific choline phospholipids in Alzheimer’s disease mimic accelerated aging. J Alzheimer’s Dis. 2018;62:841–54. Available from: https://www.medra.org/servlet/aliasResolver?alias=iospress&doi=10.3233/JAD-171036.
de Wit NM, den Hoedt S, Martinez-Martinez P, Rozemuller AJ, Mulder MT, de Vries HE. Astrocytic ceramide as possible indicator of neuroinflammation. J Neuroinflammation. 2019;16:48. Available from: https://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-019-1436-1.
Panchal M, Gaudin M, Lazar AN, Salvati E, Rivals I, Ayciriex S, et al. Ceramides and sphingomyelinases in senile plaques. Neurobiol Dis. 2014;65:193–201. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0969996114000242.
Mielke MM, Bandaru VVR, Haughey NJ, Xia J, Fried LP, Yasar S, et al. Serum ceramides increase the risk of Alzheimer disease. Neurology. 2012;79:633–41. Available from: https://www.neurology.org/doi/10.1212/WNL.0b013e318264e380.
van Kruining D, Losen M, Crivelli SM, de Jong JJA, Jansen JFA, Backes WH, et al. Plasma ceramides relate to mild cognitive impairment in middle‐aged men: The Maastricht Study. Alzheimer’s Dement Diagnosis, Assess Dis Monit. 2023;15. https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/dad2.12459
Peña-Bautista C, Álvarez-Sánchez L, Cañada-Martínez AJ, Baquero M, Cháfer-Pericás C. Epigenomics and lipidomics integration in Alzheimer disease: pathways involved in early stages. Biomedicines. 2021;9:1812. Available from: https://www.mdpi.com/2227-9059/9/12/1812.
Sakr F, Dyrba M, Bräuer A, Teipel S. Association of lipidomics signatures in blood with clinical progression in preclinical and prodromal Alzheimer’s disease. J Alzheimer’s Dis. 2022;85:1115–27. Available from: https://www.medra.org/servlet/aliasResolver?alias=iospress&doi=10.3233/JAD-201504.
Ma Y, Shen X, Xu W, Huang Y, Li H, Tan L, et al. A panel of blood lipids associated with cognitive performance, brain atrophy, and Alzheimer’s diagnosis: A longitudinal study of elders without dementia. Alzheimer’s Dement Diagnosis, Assess Dis Monit. 2020;12. https://onlinelibrary.wiley.com/doi/10.1002/dad2.12041
Anand S, Barnes JM, Young SA, Garcia DM, Tolley HD, Kauwe JSK, et al. Discovery and confirmation of diagnostic serum lipid biomarkers for Alzheimer’s disease using direct infusion mass spectrometry. J Alzheimers Dis. 2017;59:277–90. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28598845.
Clark C, Dayon L, Masoodi M, Bowman GL, Popp J. An integrative multi-omics approach reveals new central nervous system pathway alterations in Alzheimer’s disease. Alzheimers Res Ther. 2021;13:71. Available from: https://alzres.biomedcentral.com/articles/10.1186/s13195-021-00814-7.
Pan X, Nasaruddin MB, Elliott CT, McGuinness B, Passmore AP, Kehoe PG, et al. Alzheimer’s disease–like pathology has transient effects on the brain and blood metabolome. Neurobiol Aging. 2016;38:151–63. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0197458015005813.
Bai Y-R, Wang Y-Y, Meng D-L, Shi Z-L, Song X-F, Yang Z-Z, et al. Alterations of fatty acid composition and metabolism in APP/PS1 transgenic mice. Neurosci Lett. 2020;738:135401. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0304394020306716.
Demarest TG, Varma VR, Estrada D, Babbar M, Basu S, Mahajan UV, et al. Biological sex and DNA repair deficiency drive Alzheimer’s disease via systemic metabolic remodeling and brain mitochondrial dysfunction. Acta Neuropathol. 2020;140:25–47. Available from: https://link.springer.com/10.1007/s00401-020-02152-8.
Hamilton LK, Dufresne M, Joppé SE, Petryszyn S, Aumont A, Calon F, et al. Aberrant lipid metabolism in the forebrain niche suppresses adult neural stem cell proliferation in an animal model of Alzheimer’s disease. Cell Stem Cell. 2015;17:397–411. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1934590915003562.
Zeng P-Y, Tsai Y-H, Lee C-L, Ma Y-K, Kuo T-H. Minimal influence of estrous cycle on studies of female mouse behaviors. Front Mol Neurosci. 2023;16. Available from: https://www.frontiersin.org/articles/10.3389/fnmol.2023.1146109/full
Levy DR, Hunter N, Lin S, Robinson EM, Gillis W, Conlin EB, et al. Mouse spontaneous behavior reflects individual variation rather than estrous state. Curr Biol. 2023;33:1358-1364.e4. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0960982223001756.
Broestl L, Worden K, Moreno AJ, Davis EJ, Wang D, Garay B, et al. Ovarian cycle stages modulate Alzheimer-related cognitive and brain network alterations in female mice. eneuro. 2018;5:ENEURO.0132–17.2018. Available from: https://www.eneuro.org/lookup/doi/10.1523/ENEURO.0132-17.2018
Gangitano D, Salas R, Teng Y, Perez E, De Biasi M. Progesterone modulation of α5 nAChR subunits influences anxiety-related behavior during estrus cycle. Genes, Brain Behav. 2009;8:398–406. Available from: https://onlinelibrary.wiley.com/doi/10.1111/j.1601-183X.2009.00476.x.
Kundakovic M, Rocks D. Sex hormone fluctuation and increased female risk for depression and anxiety disorders: From clinical evidence to molecular mechanisms. Front Neuroendocrinol. 2022;66:101010. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0091302222000334.
Lovick TA, Zangrossi H. Effect of Estrous Cycle on Behavior of Females in Rodent Tests of Anxiety. Front Psychiatry. 2021;12. Available from: https://www.frontiersin.org/articles/10.3389/fpsyt.2021.711065/full
Zhao W, Li Q, Ma Y, Wang Z, Fan B, Zhai X, et al. Behaviors Related to Psychiatric Disorders and Pain Perception in C57BL/6J Mice During Different Phases of Estrous Cycle. Front Neurosci. 2021;15. . Available from: https://www.frontiersin.org/articles/10.3389/fnins.2021.650793/full
Francois M, Canal Delgado I, Shargorodsky N, Leu C-S, Zeltser L. Assessing the effects of stress on feeding behaviors in laboratory mice. Elife. 2022;11. . Available from: https://elifesciences.org/articles/70271
Hirshfeld-Cytron JE, Duncan FE, Xu M, Jozefik JK, Shea LD, Woodruff TK. Animal age, weight and estrus cycle stage impact the quality of in vitro grown follicles. Hum Reprod. 2011;26:2473–85. Available from: https://academic.oup.com/humrep/article-lookup/doi/10.1093/humrep/der183.
Parker GC, McKee ME, Bishop C, Coscina DV. Whole-body metabolism varies across the estrous cycle in Sprague-Dawley rats. Physiol Behav. 2001;74:399–403. . Available from: https://linkinghub.elsevier.com/retrieve/pii/S0031938401005996.
Add Comment